BCAB - Bioatla Inc
Bioatla Inc Logo

BCAB - Bioatla Inc

https://www.bioatla.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology ( ESMO ) Gastrointestinal Cancers Congress - BioAtla ( NASDAQ:BCAB )
Benzinga • 2 months, 1 week ago • score: 0.14
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. The company is headquartered in San Diego, California.

52W High
$2.53
52W Low
$0.24
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.91
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.31
EV/Revenue (<3 favorable)
1.76
P/S (TTM) (<3 favorable)
2.86
P/B (<3 favorable)
2.68
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
10.58%
Institutions (25–75% balanced)
29.76%
Shares Outstanding
58,722,000
Float
45,424,100
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
11,000,000
Gross Profit (TTM)
-51,194,000
EPS (TTM)
-1.10
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-5.75%
ROE (TTM) (>15% strong)
-8.14%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.32
Momentum
Bearish momentum
Value
0.1153
Previous
0.1032
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025